OCULAR THERAPEUTIX, INC Financing Cash Flow
OCULAR THERAPEUTIX, INC (OCUL) reported Financing Cash Flow of $2.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.58M, a 97.36% decline year-over-year.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $294.00K, a 92.97% decline year-over-year.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $449.38M, a 9857.37% increase year-over-year.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $10.36M, a 147.87% increase year-over-year.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for fiscal 2025 was $561.72M, a 69.14% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for fiscal 2024 was $332.11M, a 95.56% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for fiscal 2023 was $169.83M, a 11580.06% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) financing activities for fiscal 2022 was $1.45M, a 49.00% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $2.88M 10-Q · filed 2026-08-03 | $452.25M derived: sum of 3 quarters · filed 2026-08-03 | $462.61M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $294.00K 10-Q · filed 2026-05-05 | $449.67M derived: sum of 2 quarters · filed 2026-05-05 | $460.03M derived: sum of 3 quarters · filed 2026-05-05 | $557.83M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $449.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $459.73M derived: sum of 2 quarters · filed 2026-02-05 | $557.54M derived: sum of 3 quarters · filed 2026-08-03 | $561.72M 10-K · filed 2026-02-05 |
| 2025-09-30 | $10.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $108.16M derived: sum of 2 quarters · filed 2026-08-03 | $112.34M 10-Q · filed 2025-11-04 | $116.86M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $97.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $101.99M 10-Q · filed 2026-08-03 | $106.50M derived: sum of 3 quarters · filed 2026-08-03 | $110.68M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $4.18M 10-Q · filed 2026-05-05 | $8.70M derived: sum of 2 quarters · filed 2026-05-05 | $12.87M derived: sum of 3 quarters · filed 2026-05-05 | $15.07M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $8.69M derived: sum of 2 quarters · filed 2026-02-05 | $10.89M derived: sum of 3 quarters · filed 2026-02-05 | $332.11M 10-K · filed 2026-02-05 |
| 2024-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.37M derived: sum of 2 quarters · filed 2025-11-04 | $327.60M 10-Q · filed 2025-11-04 | $435.77M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $323.42M 10-Q · filed 2025-08-05 | $431.59M derived: sum of 3 quarters · filed 2026-02-05 | $483.52M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | $321.22M 10-Q · filed 2025-05-05 | $429.39M derived: sum of 2 quarters · filed 2026-02-05 | $481.33M derived: sum of 3 quarters · filed 2026-02-05 | $490.97M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | $108.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $160.10M derived: sum of 2 quarters · filed 2026-02-05 | $169.75M derived: sum of 3 quarters · filed 2026-02-05 | $169.83M 10-K · filed 2026-02-05 |
| 2023-09-30 | $51.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $61.58M derived: sum of 2 quarters · filed 2024-11-14 | $61.66M 10-Q · filed 2024-11-14 | $62.12M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $9.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $9.72M 10-Q · filed 2024-08-07 | $10.18M derived: sum of 3 quarters · filed 2025-03-03 | $10.55M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $78.00K 10-Q · filed 2024-05-07 | $536.00K derived: sum of 2 quarters · filed 2025-03-03 | $910.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.40M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $832.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.32M derived: sum of 3 quarters · filed 2025-03-03 | $1.45M 10-K · filed 2025-03-03 |
| 2022-09-30 | $374.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $867.00K derived: sum of 2 quarters · filed 2023-11-07 | $996.00K 10-Q · filed 2023-11-07 | $1.66M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $493.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $622.00K 10-Q · filed 2023-08-07 | $1.29M derived: sum of 3 quarters · filed 2024-03-11 | $1.97M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $129.00K 10-Q · filed 2023-05-08 | $796.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.48M derived: sum of 3 quarters · filed 2024-03-11 | $4.14M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.35M derived: sum of 2 quarters · filed 2024-03-11 | $4.01M derived: sum of 3 quarters · filed 2024-03-11 | $2.85M 10-K · filed 2024-03-11 |
| 2021-09-30 | $679.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.35M derived: sum of 2 quarters · filed 2022-11-07 | $2.18M 10-Q · filed 2022-11-07 | $166.10M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.50M 10-Q · filed 2022-08-08 | $165.42M derived: sum of 3 quarters · filed 2023-03-06 | $165.64M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | -$1.16M 10-Q · filed 2022-05-09 | $162.75M derived: sum of 2 quarters · filed 2023-03-06 | $162.97M derived: sum of 3 quarters · filed 2023-03-06 | $214.03M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $163.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $164.13M derived: sum of 2 quarters · filed 2023-03-06 | $215.20M derived: sum of 3 quarters · filed 2023-03-06 | $228.01M 10-K · filed 2023-03-06 |
| 2020-09-30 | $220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $51.28M derived: sum of 2 quarters · filed 2021-11-08 | $64.10M 10-Q · filed 2021-11-08 | $73.19M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $51.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $63.88M 10-Q · filed 2021-08-09 | $72.97M derived: sum of 3 quarters · filed 2022-02-28 | $91.58M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $12.82M 10-Q · filed 2021-05-05 | $21.91M derived: sum of 2 quarters · filed 2022-02-28 | $40.52M derived: sum of 3 quarters · filed 2022-02-28 | $45.86M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $27.70M derived: sum of 2 quarters · filed 2022-02-28 | $33.04M derived: sum of 3 quarters · filed 2022-02-28 | $75.34M 10-K · filed 2022-02-28 |
| 2019-09-30 | $18.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $23.95M derived: sum of 2 quarters · filed 2020-11-05 | $66.25M 10-Q · filed 2020-11-05 | $82.58M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $5.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $47.64M 10-Q · filed 2020-08-07 | $63.97M derived: sum of 3 quarters · filed 2020-08-07 | $75.34M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $42.30M 10-Q · filed 2020-05-08 | $58.63M derived: sum of 2 quarters · filed 2020-05-08 | $70.00M derived: sum of 3 quarters · filed 2020-05-08 | $76.71M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $16.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $27.70M derived: sum of 2 quarters · filed 2020-03-12 | $34.41M derived: sum of 3 quarters · filed 2020-03-12 | $68.64M 10-K · filed 2020-03-12 |
| 2018-09-30 | $11.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $18.09M derived: sum of 2 quarters · filed 2019-11-12 | $52.31M 10-Q · filed 2019-11-12 | $53.52M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $6.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $40.94M 10-Q · filed 2019-08-07 | $42.15M derived: sum of 3 quarters · filed 2020-03-12 | $43.67M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $34.23M 10-Q · filed 2019-05-10 | $35.43M derived: sum of 2 quarters · filed 2020-03-12 | $36.96M derived: sum of 3 quarters · filed 2020-03-12 | $37.76M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.73M derived: sum of 2 quarters · filed 2020-03-12 | $3.53M derived: sum of 3 quarters · filed 2020-03-12 | $32.01M 10-K · filed 2020-03-12 |
| 2017-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $2.33M derived: sum of 2 quarters · filed 2018-11-07 | $30.80M 10-Q · filed 2018-11-07 | $31.50M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $796.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $29.27M 10-Q · filed 2018-08-07 | $29.97M derived: sum of 3 quarters · filed 2019-03-07 | $30.04M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $28.48M 10-Q · filed 2018-05-08 | $29.17M derived: sum of 2 quarters · filed 2019-03-07 | $29.25M derived: sum of 3 quarters · filed 2019-03-07 | |
| 2016-12-31 | $693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $771.00K derived: sum of 2 quarters · filed 2019-03-07 | $585.00K 10-K · filed 2019-03-07 | |
| 2016-09-30 | $78.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$108.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | -$186.00K 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $65.70M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |